Cargando…

Spesolimab: First Approval

Spesolimab (spesolimab-sbzo; SPEVIGO(®)) is an interleukin (IL)-36 receptor antagonist being developed by Boehringer Ingelheim for the treatment of various immune-mediated disorders. In September 2022, spesolimab was approved in the USA for the treatment of generalized pustular psoriasis (GPP) flare...

Descripción completa

Detalles Bibliográficos
Autor principal: Blair, Hannah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744699/
https://www.ncbi.nlm.nih.gov/pubmed/36418672
http://dx.doi.org/10.1007/s40265-022-01801-4